KN-92

CAT:
804-HY-15517-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
KN-92 - image 1

KN-92

  • Description:

    KN-92 is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor[1][2].
  • UNSPSC:

    12352005
  • Target:

    CaMK
  • Type:

    Reference compound
  • Related Pathways:

    Neuronal Signaling
  • Applications:

    Cancer-Kinase/protease
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/kn-92.html
  • Purity:

    99.91
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles:

    O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2CN(C/C=C/C3=CC=C(Cl)C=C3)C)=O
  • Molecular Formula:

    C24H25ClN2O3S
  • Molecular Weight:

    456.98
  • References & Citations:

    [1]Smyth JT, et al. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002;277 (38) :35061-35070.|[2]An P, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007;13 (9) :1445-1448.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    No Development Reported
  • Citation 01:

    Cell Calcium. 2021 Dec:100:102483.|Commun Biol. 2025 Mar 12;8 (1) :417.|J Mol Cell Cardiol. 2022 Mar:164:110-125.|J Endocrinol. 2018 Mar;236 (3) :151-165. |Nat Metab. 2020 Sep;2 (9) :918-933.|Sci Rep. 2023 Dec 7;13 (1) :21712.
  • CAS Number:

    [176708-42-2]